SCHEMBL5550858

SCHEMBL5550858

NC(=O)C1CNCCOC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52
CYP2D6 P10635 1/20 0.52
SSTR4 P31391 14/20 0.39
SSTR1 P30872 1/20 0.36
SSTR2 P30874 1/20 0.36
SSTR3 P32745 1/20 0.36
SSTR5 P35346 1/20 0.36
SLC6A1 P30531 2/20 0.35
SLC6A11 P48066 1/20 0.35
TSHR P16473 1/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SLC6A13 Q9NSD5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1291174 0.98 KDM4E (0.50) KDM4EMAPTKMT2AATMCYP2D6
SCHEMBL1463653 0.82 SLC6A1 (0.50) KDM4EMAPTKMT2AATMCYP2D6
SCHEMBL1463655 0.82 SLC6A1 (0.50) KDM4EMAPTKMT2AATMCYP2D6
SCHEMBL31385097 0.76 SSTR4 (0.42) SSTR4SSTR1SSTR2SSTR3SSTR5
SCHEMBL31385018 0.76 SSTR4 (0.42) SSTR4SSTR1SSTR2SSTR3SSTR5
SCHEMBL25045740 0.76 SSTR4 (0.48) SSTR4SSTR1SSTR2SSTR3SSTR5
SCHEMBL20827222 0.76 CHRNB2 (0.46) SSTR4SSTR1SSTR2SSTR3SSTR5
SCHEMBL2919226 0.75 KDM4E (0.67) KDM4EMAPTKMT2AATMCYP2D6
Hydrochloric Acid SCHEMBL31385054 0.74 SSTR4 (0.41) SSTR4SSTR1SSTR2SSTR3SSTR5
Hydrochloric Acid SCHEMBL31550904 0.74 SSTR4 (0.47) SSTR4SSTR1SSTR2SSTR3SSTR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122222-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-04-17 US disclosed
WO-2023018809-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2023-02-16 WO disclosed
EP-3218372-B1 MORPHOLINE AND 1,4-OXAZEPANE AMIDES AS SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS BOEHRINGER INGELHEIM INT (DE) 2020-05-20 EP disclosed
CN-103261176-A 1, 4-oxazepane derivatives TAKAEDA CHEMICAL IND LTD 2013-08-21 CN disclosed
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors ASTRAZENECA AB (SE) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010556-A1 Thiophene derivatives as chk 1 inhibitors CHEK1, CHKA, CHEK2 KDM4E 713/4885MAPT 3514/4885KMT2A 2078/4885
US-20250122222-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE KRAS, NRAS, HRAS KDM4E 3458/4885MAPT 4805/4885KMT2A 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.